David Sterman has worked as an investment analyst for nearly two decades. He started his Wall Street career in equity research at Smith Barney, culminating in a position as Senior Analyst covering European banks. While at Smith Barney, he learned of all the tricks used by Wall Street to steer the best advice to their top clients and their own trading desk. David has also served as Managing Editor at TheStreet.com and Director of Research at Individual Investor. In addition, David worked as Director of Research for Jesup & Lamont Securities. David has made numerous media appearances over the years, primarily on CNBC and Bloomberg TV, and has a master's degree in management from Georgia Tech. David Stermanon

Analyst Articles

Despite a decade’s worth of turbulence for the market, much of it painful, it’s amazing how so many investors keep coming back to the same stocks and the same stories that have already punished their portfolios at least once. Examples of these let-downs include… Read More

For the millions of Americans who suffer from high cholesterol, Nov. 30 will be a big day. That’s when Pfizer’s (NYSE: PFE) blockbuster drug Lipitor will lose patent protection, promising massive savings for high-cholesterol patients. The $7 billion drug (according to projected 2011 sales) also represents a big deal for… Read More

If you’ve visited the grocery store lately, then you’ve probably noticed prices for basic food items such as bread and ground beef have soared this year. The increase is mainly as result of skyrocketing prices for commodities. Wheat prices, for instance, have climbed 65% just in the past year, while… Read More

On Tuesday, I brought my Scarcity & Real Wealth subscribers some important news, some of it bad, some of it good. The bad news: rare earth miner Molycorp (NYSE: MCP), one of my favorite stocks in this exciting sector, was down 22% on Tuesday, Sept. 20. Since then, it’s fallen… Read More